ari-0001
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 11, 2021 (NCT04778579)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05641428 | Phase 2 | Oct 18, 2022 | HOVON - Dutch Haemato-Oncology Association, University of Groningen |
| NCT04778579 | Phase 2 | May 11, 2021 | Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universidad Carlos III Madrid |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HOVON - Dutch Haemato-Oncology Association | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Institut d'Investigacions Biomèdiques August Pi i Sunyer | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Universidad Carlos III Madrid | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Groningen | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1